Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax + Osimertinib in EGFR-mutant NSCLC
NCT02520778Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2016
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navitoclax in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoints: Incidence of toxicity up to 2 years and Feasibility of the combination therapy in T790M+ lung cancer up to 12 weeks. Started Aug 2016; status: completed.
02
Drugs
navitoclax
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02520778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520778.